Zobrazeno 11 - 20
of 157
pro vyhledávání: '"35"'
Autor:
Nancy Tray, Karen Hiotis, Deborah Axelrod, Victor Ty, Judith D. Goldberg, Farbod Darvishian, Maryann Kwa, Yelena Novik, Sylvia Adams, Amber A. Guth, James L. Speyer, Adriana Heguy, Douglas K. Marks
Publikováno v:
Cancer Research. 80:OT1-01
BACKGROUND: Receptor activator of NF-kB (RANK) and its ligand (RANKL) have a well-established role in osteoclast-driven bone remodeling, however RANK/RANKL expression can also be seen on mammary epithelial cells and immune cells (IC). In breast cance
Autor:
George A. Dominguez, Amit Kumar, Alexander Polo, John Roop, Anthony Campisi, Dmitry I. Gabrilovich
Publikováno v:
Cancer Research. 80:P5-01
Breast cancer screening, detection, and diagnosis relies heavily upon mammography, but due to breast pathology and the intrinsic limits of detection, mammogram-based procedures result in many false positives causing an increased risk for overdiagnosi
Publikováno v:
Cancer Research. 75:P1-10
Introduction: With a reported incidence of 2-12% in breast biopsy specimens, the appropriate management of atypical ductal hyperplasia (ADH) remains in evolution. At present, the optimal screening guidelines for patients with high-risk breast lesions
Publikováno v:
Cancer Research. 79:3316-3316
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome, caused primarily by germline pathogenic TP53 variants and associated with a very high lifetime cancer risk which reaches approximately 100% by age 60 years. Individua
Autor:
G. Liu, Q-X Han, X-C Yang, Z. Shen, X Yan, Y-F Hou, Z-B Liu, Z-M Shao, J Wu, Zhengjun Hu, X Huang, C. Chen, G. Di, J-S Lu
Publikováno v:
Cancer Research. 73:P2-07
Background: Germline mutations in BRCA1, BRCA2 and other genes predispose to high risks of breast cancer. Genetic testing for germline mutations in BRCA1 and BRCA2 has been widely used in women with severe family history of breast or ovarian cancer i
Autor:
Masakazu Toi, Zhipeng Wang, Kazuharu Shimizu, Norikazu Masuda, Takayuki Ueno, Yoshiki Mikami, Fumiaki Sato, Akira Myomoto, Satoko Takizawa, Gozoh Tsujimoto
Publikováno v:
Cancer Research. 72:P5-10
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Autor:
P Pronzato, J Plun-Favreau
Publikováno v:
Cancer Research. 71:P1-10
Background: The Oncotype DX® Breast Cancer Test is a validated 21-gene assay that predicts 10 year risk of recurrence and the likelihood of benefit from adjuvant chemotherapy in early-stage, node-negative ER+ breast cancer. The cost-effectiveness of
Autor:
Min-Hsien Wu, Siou-Ru Ye, Hung-Ming Wang, Ting-Hsiuan Yeh, Jason Chia-Hsun Hsieh, Jane Ying-Chieh Lee, Yung-Chang Lin, Nina Ming-Jung Lin
Publikováno v:
Cancer Research. 77:3790-3790
Background: Circulating tumor cell (CTC) has been prognostic and predictive in numerous types of cancer; however, its role in early diagnosis of relapse remains unclear. Methods: Eighty-six patients were prospectively enrolled between March 2015 and
Autor:
Charles E. Cox, Shiyu Wang, Lisa Blumencranz, Amy Truitt, Andrea Menicucci, Steven C. Shivers, Mehran Habibi, Peter W. Blumencranz, William Audeh, Jolanta L. Baginski, Geza Acs
Publikováno v:
Cancer Research. 81:PS6-41
Background: Elderly breast cancer (BC) patients are an understudied population, with limited evidence regarding treatment options and outcomes and a lack of research involving prognostic multigene assays for this group. One study in patients 65-89 ye
Autor:
Lei Lei, Tzu-Pin Lu, Zi-Yan Yang, Xian-Yuan Miao, Xiao-jia Wang, Hung-Chun Skye Cheng, Han-Ching Chan, Jia-Huan Huang
Publikováno v:
Cancer Research. 81:PS6-51
Purpose: Dutch clinical risk criteria (low-risk definition: age > 35 years and (grade 1 with tumor ≤3cm, grade 2 with tumor ≤2cm, or grade 3 with tumor ≤1cm) have been used to stratify the benefit of MammaPrint and Oncotype DX for the decision-